Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi

Executive Summary

Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls... 


Related Content

Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
Eight Things To Know From Novartis' Third Quarter Call
Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal
Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Pfizer CEO Read Will Pass The Torch To Bourla In 2019
Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor
GSK's Big Reveal: An R&D Overhaul Poised To Yield Long-Term Cultural Change
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
Sun Rises For GSK's Trelegy And Shingrix While It Sets For Advair


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts